Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $33.37.

NTLA has been the subject of a number of analyst reports. Chardan Capital restated a "buy" rating and issued a $68.00 price target on shares of Intellia Therapeutics in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. Canaccord Genuity Group reduced their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Citigroup reduced their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Wedbush restated a "neutral" rating and issued a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th.

Insider Buying and Selling

In related news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 12,799 shares of company stock worth $156,089 over the last three months. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Raymond James Financial Inc. bought a new position in Intellia Therapeutics during the fourth quarter valued at approximately $4,793,000. Swiss National Bank raised its position in Intellia Therapeutics by 6.0% during the fourth quarter. Swiss National Bank now owns 189,700 shares of the company's stock valued at $2,212,000 after purchasing an additional 10,700 shares during the period. Commonwealth Equity Services LLC raised its position in Intellia Therapeutics by 26.0% during the fourth quarter. Commonwealth Equity Services LLC now owns 30,764 shares of the company's stock valued at $359,000 after purchasing an additional 6,343 shares during the period. Thrivent Financial for Lutherans raised its position in Intellia Therapeutics by 111.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 64,211 shares of the company's stock valued at $749,000 after purchasing an additional 33,878 shares during the period. Finally, Intech Investment Management LLC raised its position in Intellia Therapeutics by 22.5% during the fourth quarter. Intech Investment Management LLC now owns 34,544 shares of the company's stock valued at $403,000 after purchasing an additional 6,341 shares during the period. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock traded up $0.82 during mid-day trading on Thursday, reaching $13.60. 4,114,900 shares of the stock traded hands, compared to its average volume of 4,522,027. The stock has a market capitalization of $1.41 billion, a PE ratio of -2.60 and a beta of 2.21. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $27.42. The business's 50-day moving average is $9.96 and its 200-day moving average is $9.38.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The business's quarterly revenue was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.12) earnings per share. Equities analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.